Marker Therapeutics Inc (MRKR)
4.14
-0.09
(-2.13%)
USD |
NASDAQ |
May 10, 16:00
4.14
0.00 (0.00%)
After-Hours: 19:09
Marker Therapeutics Revenue (Quarterly)
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2023 | 3.50M |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | 0.4668M |
| March 31, 2020 | |
| December 31, 2019 | 0.2132M |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | 0.206M |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | 0.1831M |
| June 30, 2017 | |
| March 31, 2017 |
| Date | Value |
|---|---|
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 | |
| June 30, 2013 | |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 | |
| March 31, 2012 | |
| December 31, 2011 | |
| September 30, 2011 | |
| June 30, 2011 | |
| March 31, 2011 | |
| December 31, 2010 |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.2132M
Minimum
Dec 2019
3.50M
Maximum
Mar 2023
1.393M
Average
0.4668M
Median
Jun 2020
Revenue (Quarterly) Benchmarks
| AIM ImmunoTech Inc | 0.065M |
| Perspective Therapeutics Inc | -5.239M |
| Protalix BioTherapeutics Inc | 10.49M |
| Electromed Inc | 13.69M |
| Armata Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.803M |
| Total Expenses (Quarterly) | 2.938M |
| EPS Diluted (Quarterly) | -0.32 |
| Enterprise Value | 22.55M |
| Earnings Yield | -22.71% |
| Normalized Earnings Yield | -54.35 |